Anavex Life Sciences Corp. Book Value 2011-2025 | AVXL

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Anavex Life Sciences Corp.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
94.9 M	120 M	142 M	142 M	151 M	27.2 M	20.3 M	20.5 M	24.3 M	6.31 M	12.8 M	193 K	-2.46 M	-2.88 M	-1.14 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
151 M	-2.88 M	50.4 M

Quarterly Book Value Anavex Life Sciences Corp.

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
91 M	99.8 M	111 M	120 M	130 M	135 M	136 M	142 M	147 M	145 M	135 M	142 M	160 M	160 M	157 M	151 M	157 M	162 M	54.3 M	27.2 M	34.5 M	34.5 M	31.4 M	20.3 M	25.3 M	25.3 M	22.1 M	26.2 M	24.4 M	24.4 M	28.3 M	24.3 M	27.8 M	27.8 M	21.4 M	6.31 M	7.33 M	7.07 M	11.5 M	12.8 M	12.8 M	12.8 M	473 K	193 K	193 K	193 K	-1.67 M	-2.46 M	-2.46 M	-2.46 M	-3.33 M	-2.88 M	-2.88 M	-2.88 M	-2.48 M	-1.14 M	-1.14 M	-1.14 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
162 M	-3.33 M	51.8 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	106 M	$ 4.75	-0.84 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	156 M	$ 3.01	-1.15 %	$ 233 M	USA
Aeglea BioTherapeutics AGLE	518 M	-	-	$ 1.01 B	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 0.24	35.16 %	$ 522 M	Israel
Aptorum Group Limited APM	11.8 M	$ 1.14	-2.56 %	$ 6.22 M	China
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Ascendis Pharma A/S ASND	-106 M	$ 210.29	-1.18 %	$ 5 B	Danmark
Aptevo Therapeutics APVO	4.76 M	$ 0.52	-44.24 %	$ 144 K	USA
Celldex Therapeutics CLDX	747 M	$ 26.14	-2.57 %	$ 1.68 M	USA
Cellectar Biosciences CLRB	-13.8 M	$ 2.6	-5.8 %	$ 31.8 M	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.09	-0.16 %	$ 7.43 B	Australia
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
BioVie BIVI	19 M	$ 1.2	-5.91 %	$ 1.77 M	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	39.5 M	-	-15.15 %	$ 60.3 M	Britain
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
BioNTech SE BNTX	19.4 B	$ 94.48	-0.58 %	$ 27.2 B	Germany
Amphastar Pharmaceuticals AMPH	732 M	$ 26.87	0.21 %	$ 1.3 B	USA
BeiGene, Ltd. BGNE	3.33 B	-	0.49 %	$ 251 B	Cayman-islands
Anika Therapeutics ANIK	271 M	$ 9.5	0.16 %	$ 139 M	USA
Bellicum Pharmaceuticals BLCM	20.1 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	142 M	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	195 M	-	-	$ 546 M	USA
Dynavax Technologies Corporation DVAX	597 M	$ 15.4	0.1 %	$ 2 B	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Calithera Biosciences CALA	49.1 M	-	-10.95 %	$ 876 K	USA
Eton Pharmaceuticals ETON	15.5 M	$ 16.87	-0.71 %	$ 433 M	USA
Axon Enterprise AXON	2.33 B	$ 580.0	-1.89 %	$ 43.9 B	USA
Evogene Ltd. EVGN	39.9 M	$ 1.03	-1.9 %	$ 27.9 M	Israel
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Exelixis EXEL	2.24 B	$ 46.44	-0.15 %	$ 13.5 B	USA
Aytu BioScience AYTU	124 M	$ 2.5	-1.19 %	$ 15.7 M	USA
AstraZeneca PLC AZN	40.9 B	$ 92.68	0.25 %	$ 96.9 B	Britain
Foghorn Therapeutics FHTX	-45.5 M	$ 5.37	-0.56 %	$ 295 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Catalyst Biosciences CBIO	78.5 M	$ 12.3	-0.57 %	$ 810 M	USA